Renal failure in multiple myeloma and its treatment

Czech version

Authors: Romana Ryšavá
Authors‘ workplace: Klinika nefrologie 1. LF UK a VFN Praha
Published in: Vnitř Lék 2020; 66(7): 425-431
Category:

Overview

Renal failure is a serious complication of multiple myeloma, and up to 50% of patients with this most frequent haematological malignancy may develop some form of renal impairment. The aetiology of renal damage is multifactorial, but increased production of free light chains that are filtered into the urine is crucial for the development of renal failure and could be associated with distal tubule involvement (myeloma kidney, light chain cast nephropathy) or with fully developed Fanconi syndrome in proximal tubule damage (proximal tubulopathy, light chain proximal tubulopathy). Glomerular damage most often manifests as AL amyloidosis or light chain deposition disease; both cause severe nephrotic syndrome. Early and adequate chemotherapy in association with symptomatic treatment can lead to rapid reduction of serum light chain concentration which is necessary to prevent development of renal failure. At present, effective therapeutic procedures can be used for this purpose, where especially a triple combination of treatment containing one of the proteasome inhibitors (bortezomib, carfilzomib or ixazomib) is able to elicit a haematological response within a few days. If there is a good haematological response to treatment, up to 50% of patients with renal failure will restore their renal function. Renal function repair can be accelerated by removing light chains from serum by dialysis with high-cutoff membrane (HCO-HD). Using this procedure can increase the chance of dialysis independence in more than 60% of patients with renal failure. Data from previously published studies on HCO-HD (MYRE or EuLITE study) have not yielded as optimistic results as originally expected, however, HCO-HD could be beneficial for some subgroup of patients with renal failure in myeloma kidney. Despite the fact that overall prognosis and survival of patients with multiple myeloma have dramatically improved, the condition with renal failure in these patients remains serious.

Keywords:

bortezomib – dialysis with high-cutoff membrane – Multiple myeloma – cast nephropathy – renal failure

Sources

1. Tsakiris DJ, Stel VS, Finne P, et al. Incidence and outcome of patients starting renal replacement therapy for end- stage renal disease due ti multiple myeloma or light- chain deposition disease: an ERA -EDTA Registry study. Nephrol Dial Transplant 2010; 25: 1200–1206.

2. Knudsen LM, Hippe E, Hjorth M, et al. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207–212.

3. Dimopoulos MA, Terpos E, Chanan -Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976–4984.

4. Wirk B. Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplantation 2011; 46: 771–783.

5. Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol 2006; 17: 2533–2545.

6. Heher EC, Rennke HG, Laubach JP, et al. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol 2013; 8: 2007–2017.

7. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulins fragments. J Exp Med 1967; 126: 207–221.

8. Ying WZ, Wang PX, Sanders PW. Pivotal role of apoptosis signal- regulating kinase 1 in monoclonal free light chain -mediated apoptosis. Am J Patol 2012; 180: 41–47.

9. Sengul S, Zwizinski C, Batuman V. Role of MAPK pathways in the light chain induced cytokine production in human proximal tubule cells. Am J Renal Physiol 2003; 284: F1245–F1254.

10. Cockwell P, Hutchison CA. Management options for cast nephropathy in multiple myeloma. Current Opinion in Nephrology and Hypertension 2010; 19: 550–555.

11. Herrera GA, Sanders PW. Paraproteinemic renal diseases that involve the tubulo-interstitium. Contrb Nephrol 2007; 153: 105–115.

12. Ryšavá R AL. amyloidosis with renal involvement. Kidney Blood Pres Res 2007; 30: 359–364.

13. Zhu L, Herrera GA, Murphy -Ullrich JE, et al. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor- beta. Am J Pathol 1995; 147: 375–385.

14. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.

15. Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet 2014; 15: e538–e548.

16. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and responce assessment of multiple myeloma. Leukemia 2009; 23: 3–9.

17. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.

18. Hutchison CA, Basnayake K, Cockwell P. Serum free light chain assessment in monoclonal gammapathy and kidney disease. Nat Rev Nephrol 2009; 5: 621–627.

19. Bradwell AR, Harding SJ, Fourrier NJ, et al. Assessment of monoclonal gammapathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 2009; 55: 1646–1655.

20. Hutchison CA, Plant T, Drayson M. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BCM Nephrology 2008; 9: 11–19.

21. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum- free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215–224.

22. Haubitz M, Peest D. Myeloma – new approaches to combined nephrological-haematological management. Nephrol Dial Transplant 2006; 21: 582–590.

23. Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib- based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411–1414.

24. Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethazone -containing regimes and tje impact of novel agents. Haematologica 2007; 92: 546–549.

25. Chanan- Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma with advanced renal failure. Blood 2007; 109: 2604–2606.

26. Dimopoulos MA, Roussou M, Gavriatopoulos M, et al. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J 2017; 7: e571.

27. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143: 777–784.

28. Leung N, Gertz MA, Zeldenrust SR. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73: 1282–12888.

29. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for mulitple myeleoma. In vitro and in vivo studies. J Am Soc Nephrol 2007; 18: 886–895.

30. Hutchison CA, Bradwell AR, Cook M, et al. Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut- Off Hemodialysis. Clin J Am Soc Nephrol 2009; 4: 745–754.

31. Gerth HU, Pohlen M, Görlich D, et al. Impact of High- Cut- Off Dialysis on Renal Recovery in Dialysis -Dependent Multiple Myeloma Patients: Results from a Case -Control Study. Plos One 6; 11: e0154993.

32. Bridoux F, Carron PL, Pegourie B, et al. Effect of high- cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy. A randomized clinical trial. JAMA 2017; 318: 2099–2110.

33. Hutchison CA, Cockwell P, Moroz V, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol 2019; 6(4): e217-e228.

34. Finkel K, Fabbrini P. High cut -off hemodialysis for myeloma cast nephropathy – do we finally have an answer? J Onco -Nephrol 2017; 1: 67–70.

35. Haynes RJ, Read S, Collins GP, et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2010; 25: 419–426.

36. Parikh GC, Amjad AL, Saliba RM, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812–816.

37. Raab MS, Breitkreutz I, Hundemer M, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis- dependent renal failure. Haematologica 2006; 11: 1555–1558.

38. Caillard S, Agodoa LY, Bohen EM, et al. Myeloma, Hodgkin disease and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006; 81: 888–895.

39. Bridoux F, Leung N, Hutchison C, et al. Diagnosis of monoclonal gammopathy of renal signifikance. Kidney Int 2015; 87: 698–711.

40. Sethi S, Rajkumar SV, D’Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin -associated renal diseases. J Am Soc Nephrol 2018; 29: 1810–1823.